Patents by Inventor Timothy Michael Lukas

Timothy Michael Lukas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of a PI3K/mTOR-inhibitor for intravenous administration
    Patent number: 10660959
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 26, 2020
    Assignee: Pfizer Inc.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • FORMULATIONS OF A PI3K/MTOR-INHIBITOR FOR INTRAVENOUS ADMINISTRATION
    Publication number: 20190105390
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Application
    Filed: November 13, 2018
    Publication date: April 11, 2019
    Applicant: PFIZER INC.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • Formulations of a PI3K/mTor-inhibitor for intravenous administration
    Patent number: 10172942
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: January 8, 2019
    Assignee: Pfizer Inc.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • FORMULATIONS OF A PI3K/MTOR-INHIBITOR FOR INTRAVENOUS ADMINISTRATION
    Publication number: 20170360935
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Application
    Filed: December 10, 2015
    Publication date: December 21, 2017
    Applicant: PFIZER INC.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • TREATMENT OF PULMONARY HYPERTENSION
    Publication number: 20120095006
    Abstract: This invention relates to the use of certain cyclic guanosine 3?,5?-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.
    Type: Application
    Filed: December 16, 2011
    Publication date: April 19, 2012
    Inventors: Ghazwan Saleem Butrous, Timothy Michael Lukas, Ian Machin
  • Treatment of Pulmonary Hypertension
    Publication number: 20090239883
    Abstract: This invention relates to the use of certain cyclic guanosine 3?,5?-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.
    Type: Application
    Filed: January 16, 2009
    Publication date: September 24, 2009
    Inventors: Ghazwan Saleem Butrous, Timothy Michael Lukas, Ian Machin
  • Antiparasitic formulations
    Patent number: 6797701
    Abstract: A long-acting antiparasitic formulation suitable for topical application including: (a) 0.1-50% w/v an avermectin or milbemycin having activity against endo- and/or ectoparasites; (b) 1-50% v/v a di(C2-4 glycol) mono(C1-4 alkyl) ether; (c) an optional antioxidant; and (d) an optional skin acceptable volatile solvent q.s. v/v.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: September 28, 2004
    Assignee: Pfizer Inc.
    Inventors: Timothy Michael Lukas, Stephen Richard Wicks
  • Antiparasitic formulation
    Patent number: 6699847
    Abstract: Long-acting antiparasitic formulations of doramectin, suitable for injection, are described herein.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: March 2, 2004
    Assignee: Pfizer Inc.
    Inventors: Stephen Richard Wicks, Timothy Michael Lukas, Valerie Denise Harding, Snezana Milojevic
  • Antiparasitic formulation
    Publication number: 20020142972
    Abstract: Long-acting antiparasitic formulations of doramectin, suitable for injection, are described herein.
    Type: Application
    Filed: November 7, 2001
    Publication date: October 3, 2002
    Applicant: Pfizer Inc.
    Inventors: Stephen Richard Wicks, Timothy Michael Lukas, Valerie Denise Harding, Snezana Milojevic
  • Antiparasitic formulations
    Publication number: 20020028780
    Abstract: A long-acting antiparasitic formulation suitable for topical application including:
    Type: Application
    Filed: October 16, 2001
    Publication date: March 7, 2002
    Inventors: Timothy Michael Lukas, Stephen Richard Wicks